title: Should anti-mesothelin therapies be explored in lung cancer?
authors.affiliation: a Thoracic and GI Oncology Branch, Center for Cancer Research , National Cancer Institute , Bethesda , MD , USA.
authors.forename: Anish
authors.initials: A
authors.lastname: Thomas
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D015195:Drug Design; D058851:GPI-Linked Proteins / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D000090204:Mesothelin; D058990:Molecular Targeted Therapy
chemical_list: D000970:Antineoplastic Agents; D058851:GPI-Linked Proteins; D000090204:Mesothelin
keywords: Mesothelin; NSCLC; antibody-drug conjugate; immunotoxin; lung adenocarcinoma